Shares of clinical stage biotechnology company Longeveron Inc. (LGVN) are rising more than 20% Tuesday morning at $3.89.
Longeveron today reported long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS).
The data showed that 100% of the 10 patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-BTM during their Stage 2 surgery.
LGVN has traded in the range of $2.50 – 9.34 in the last 1 year.
Source: Read Full Article
Lates News:
-
Deere & Company Drops On Tepid Outlook
-
BTC: Jimmy Song Goes to El Salvador To Teach $4,000 Two-Day Bitcoin Programming Course
-
Applied Digital Rallies As Co. Sees Strong Demand For Its AI Cloud Service
-
Bitcoin (BTC/USD) Price Analysis – 6 July 2023
-
Riding the Crypto Wave: Novogrtz’s Investment Strategy in Uncertain Economic Times